Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-PSMA-I&T vs hormone therapy in metastatic castration-resistant prostate cancer
2022-501493-19-00Phase 3Authorised
- Sponsor
- Curium
- Start
- Dec 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177 PSMA I&T in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Curium. Primary endpoint: Radiographic progression-free survival (rPFS). Planned start Dec 2022; status: authorised.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2022-501493-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501493-19-00.